Radiopaque fibers and filtration matrices

• US 8,052,714 B2
• Filed: 11/21/2006
• Issued: 11/08/2011
• Est. Priority Date: 11/22/2005
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Inventors: Ebner, Bruce W., Galdonik, Jason A., Ogle, Matthew F.
• Primary Examiner(s): Hughes; S. Thomas
• Assistant Examiner(s): EASTWOOD, DAVID C
• Application Number:
  US11/603,315
• Publication Number:
  US 20070172526A1
• Time in Patent Office: 1,813 Days
• Field of Search: 606/191, 606/198, 606/200, 604104-109
• US Class Current: 606/200
• CPC Class Codes: A61K 49/0409 Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound

Abstract

Medical devices with radiopaque three dimensional filtration matrices provide for improved visualization of the device within a vessel. In some embodiments, the three dimensional filtration matrix comprises fibers, such as surface capillary fibers. Visualization of the three dimensional filtration matrix provides for an evaluation of the proper deployment of the three dimensional filtration matrix. Radiopaque surface capillary fibers can be advantageously incorporated into other medical devices. Radiopaque surface capillary fibers can be formed by extrusion of a radiopaque polymer or polymer composite.

Claims

1. A medical device for deployment inside a vessel comprising a radiopaque filter element comprising a plurality of fibers having a delivery configuration with a low profile relative to a longitudinal axis having a first peak radiopacity and an extended configuration with the fibers forming a three dimensional filtration matrix having a large profile relative to the longitudinal axis having a second peak radiopacity,

wherein the second peak radiopacity is visibly greater than the first peak radiopacity,

wherein the fibers are polymer surface capillary fibers with at least one channel that extends substantially parallel to the length of the polymer surface capillary fiber and along at least a portion of the length of the polymer surface capillary fiber, and

wherein the filter element further comprises an unwoven combination of polymer surface capillary fibers and one or more radiopaque metal wires or polymer surface capillary fibers with a radiopaque metal coating, or a composite polymer surface capillary fiber structure of polymer and radiopaque inorganic particles,

said medical device further comprising an integrated guide structure comprising an overtube and a corewire extending within the overtube, wherein one end of the fibers in the bundle is operably connected to the corewire and a second end of the fibers is operably connected to the overtube, the relative movement of the overtube and corewire resulting in a transition of the filter element between the delivery configuration and the extended configuration.

2. The medical device of claim 1 further comprising a tether operably connected to the filter element.

3. The medical device of claim 1 wherein the filter element comprises the polymer surface capillary fibers comprising a polymer with a radiopaque coating.

4. The medical device of claim 1 wherein the filter element comprises an unwoven combination of polymer surface capillary fibers and one or more radiopaque metal wires.

5. The medical device of claim 1 further comprising radiopaque marker bands located near the respective ends of the fiber bundle.

6. The medical device of claim 1 wherein the filter element comprises a composite polymer surface capillary fiber structure of a polymer and radiopaque inorganic particles.

7. The medical device of claim 6 wherein the composite comprises at least about 15 weight percent inorganic particles and wherein the inorganic particles are radiopaque.

8. The medical device of claim 1 wherein the filter element comprises about 2 weight percent to about 40 weight percent of radiopaque material.

9. The medical device of claim 1 wherein the second peak radiopacity of the deployed configuration is at least 25% greater than the first peak radiopacity of the delivery configuration.